Lixte Biotechnology (NASDAQ:LIXT) Trading Up 3.9% – Should You Buy?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT)’s share price was up 3.9% during mid-day trading on Wednesday . The company traded as high as $3.43 and last traded at $3.16. Approximately 133,437 shares traded hands during trading, an increase of 101% from the average daily volume of 66,363 shares. The stock had previously closed at $3.04.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lixte Biotechnology in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Lixte Biotechnology Price Performance

The stock has a 50 day moving average price of $3.97 and a two-hundred day moving average price of $4.24. The company has a market capitalization of $23.64 million, a price-to-earnings ratio of -2.68 and a beta of 0.94.

Lixte Biotechnology (NASDAQ:LIXT) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.33) earnings per share (EPS) for the quarter.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.